Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.

Chine

Retour au propriétaire
1-2 de 2 pour Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. Trier par
Recheche Texte
Affiner par
Juridiction
        International 1
        États-Unis 1
Date
2023 1
2021 1
Classe IPC
A61K 36/756 - Phellodendron, p. ex. chêne-liège 2
A61K 36/185 - Magnoliopsida (dicotylédones) 1
A61K 36/288 - Taraxacum (pissenlit) 1
A61K 36/355 - Lonicera (chèvrefeuille) 1
A61K 36/489 - Sophora, p. ex. sophora japonica 1
Voir plus
Statut
En Instance 1
Enregistré / En vigueur 1
Résultats pour  brevets

1.

TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING EGFR-TKIS RELATED SKIN RASH AND USE THEREOF

      
Numéro d'application 17787337
Statut En instance
Date de dépôt 2020-12-18
Date de la première publication 2023-02-23
Propriétaire
  • YANGTZE RIVER PHARMACEUTICAL GROUP GUANGZHOU HAIRUI PHARMACEUTICAL CO., LTD. (Chine)
  • YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (Chine)
  • YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU LONGFENGTANG TRADITIONAL CHINESE MEDICINE CO., LTD. (Chine)
Inventeur(s) Lin, Lizhu

Abrégé

A traditional Chinese medicine composition for treating EGFR-TKIs related skin rash and a use thereof, characterized by comprising a therapeutically effective amount of the following components: honeysuckle, dandelion, radix sophorae flavescentis, Kochia scoparia, Dictamnus dasycarpus, tree peony root barks, Cortex Phellodendri, and peppermint. The traditional Chinese medicine composition for treating EGFR-TKIs related skin rash has a certain effect for the treatments of EGFR-TKIs related skin rash and paronychia. The raw materials coordinate with each other, thus can play medicinal effects to a maximum extent, thus significantly improving life quality of patients and prolonging survival period of patients. In addition, the traditional Chinese medicine composition also has advantages of non-toxic side effects and lower treatment cost.

Classes IPC  ?

  • A61K 36/185 - Magnoliopsida (dicotylédones)
  • A61K 36/288 - Taraxacum (pissenlit)
  • A61K 36/355 - Lonicera (chèvrefeuille)
  • A61K 36/489 - Sophora, p. ex. sophora japonica
  • A61K 36/534 - Mentha (menthe)
  • A61K 36/65 - Paeoniaceae (famille de la pivoine), p. ex. pivoine chinoise
  • A61K 36/71 - Ranunculaceae (famille du bouton d'or), p. ex. pied d'alouette, hépatique, hydrastis, ancolie
  • A61K 36/756 - Phellodendron, p. ex. chêne-liège

2.

TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING EGFR-TKIS RELATED SKIN RASH AND USE THEREOF

      
Numéro d'application CN2020137615
Numéro de publication 2021/121388
Statut Délivré - en vigueur
Date de dépôt 2020-12-18
Date de publication 2021-06-24
Propriétaire YANGTZE RIVER PHARMACEUTICAL GROUP GUANGZHOU HAIRUI PHARMACEUTICAL CO., LTD. (Chine)
Inventeur(s) Lin, Lizhu

Abrégé

A traditional Chinese medicine composition for treating EGFR-TKIs related skin rash, characterized by comprising a therapeutically effective amount of the following components: honeysuckle, dandelion, radix sophorae flavescentis, Kochia scoparia, Dictamnus dasycarpus, tree peony root barks, Cortex Phellodendri, and peppermint. The traditional Chinese medicine composition for treating EGFR-TKIs related skin rash has a certain effect for the treatments of EGFR-TKIs related skin rash and paronychia. The raw materials coordinate with each other, thus can play medicinal effects to a maximum extent, thus significantly improving life quality of patients and prolonging survival period of patients. In addition, the traditional Chinese medicine composition also has advantages of non-toxic side effects and lower treatment cost.

Classes IPC  ?

  • A61K 36/756 - Phellodendron, p. ex. chêne-liège
  • A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques